Survival of BCLC-B hepatocellular carcinoma patients after liver resection combined with microwave coagulation therapy vs transarterial chemoembolization
10.3760/cma.j.issn.1007-631X.2017.05.001
- VernacularTitle:肝切除联合微波固化治疗BCLC-B期肝细胞癌的生存预后分析
- Author:
Zhenyu YANG
;
Xilin DU
;
Shixiong LEI
;
Kai TAN
;
Tao YANG
;
Jianguo LU
- Keywords:
Carcinoma,hepatocellular;
Microwaves;
Chemotherapy,cancer,regional perfusion
- From:
Chinese Journal of General Surgery
2017;32(5):381-385
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the prognosis of patients with BCLC-B hepatocellular carcinoma (HCC) receiving LR + MCT vs TACE.Methods BCLC-B HCC patients undergoing LR + MCT (107 cases) and TACE (65 cases) were retrospectively evaluated,in terms of 30-day mortality rate,the median survival,early and long term survival rate and complications.Results The hospital mortality rate was similar between the two groups (x2 =0.285,P =0.593).However,the LR + MCT group were with a significantly higher postoperative complication rate than the TACE group (x2 =4.694,P =0.03).At the same time,the LR + MCT group had significantly higher median Survival rates (x2 =9.135,P =0.003),but,there was no statistical difference for five-year survival (x2 =4.767,P =0.434).Conclusions LR + MCT are as safe as TACE for patients with BCLC-B HCC,and it provides longer median survival rates.